TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions
about
Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancerExpanding antitumor therapeutic windows by targeting cancer-specific nicotinamide adenine dinucleotide phosphate-biogenesis pathwaysThe clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updatesComplete absence of M2-pyruvate kinase expression in benign pancreatic ductal epithelium and pancreaticobiliary and duodenal neoplasiaA metabolic switch controls intestinal differentiation downstream of Adenomatous polyposis coli (APC).Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection.Overexpression of the M2 isoform of pyruvate kinase is an adverse prognostic factor for signet ring cell gastric cancerPyruvate kinase M2 is a novel diagnostic marker and predicts tumor progression in human biliary tract cancerOvarian cancer biomarkers: a focus on genomic and proteomic findings.Upregulation of plasma C9 protein in gastric cancer patients.ITIH3 is a potential biomarker for early detection of gastric cancer.An outlook on ovarian cancer and borderline ovarian tumors: focus on genomic and proteomic findingsSerum tumor markers in pancreatic cancer-recent discoveries.Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells.Glucose metabolic phenotype of pancreatic cancer.Alteration of cellular metabolism in cancer cells and its therapeutic prospects.Evidence of Altered Glycosylation of Serum Proteins Prior to Pancreatic Cancer Diagnosis.
P2860
Q24645339-317305E8-9BA2-4C2A-B926-874A3FD853ABQ26861539-CA58A3A4-C8A7-4425-ACE1-F613B99D9B78Q26865015-A378E6CB-51CF-4F58-B6BE-0E41558D903AQ33503436-40686BB7-C16B-4AE7-A423-EC04C77227B2Q33554605-76E7C5D8-2841-4867-9713-C716F1760CD0Q34275247-6A5E249F-1A83-4F9C-B71C-228DEC74B105Q36166992-55EE55FB-A50E-4C23-8FFC-CFB4BE0EA6D0Q36381459-A2CD7667-3918-4F77-BDEA-4883DD407651Q37119992-1BCBC845-B7AD-4A10-955B-4BCFA2E9DB6FQ37139908-2E809096-E804-4FEC-BC56-9A0FA2BB23A6Q37139950-FEA3D7BF-81CF-4A44-8F0A-B58AF46AFB3BQ37260040-BCDAA261-DE5B-4D4F-8935-42AC73757947Q38166573-549B6998-292D-46C8-83E2-E047DB5234A9Q38297287-5B380FAC-36AA-46E2-8EC9-3EE75602AD64Q38791962-243B27BF-76CC-4DED-A2B8-206E8E70981AQ41162185-3324D5F8-3B00-4D39-8BDA-4E63C308796FQ47177056-E43CE11E-9904-4B07-B3C5-76040BC81A03
P2860
TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions
description
1999 nî lūn-bûn
@nan
1999 թուականին հրատարակուած գիտական յօդուած
@hyw
1999 թվականին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
TUM2-PK (pyruvate kinase type ...... tastasizing pancreatic lesions
@ast
TUM2-PK (pyruvate kinase type ...... tastasizing pancreatic lesions
@en
TUM2-PK (pyruvate kinase type ...... tastasizing pancreatic lesions
@nl
type
label
TUM2-PK (pyruvate kinase type ...... tastasizing pancreatic lesions
@ast
TUM2-PK (pyruvate kinase type ...... tastasizing pancreatic lesions
@en
TUM2-PK (pyruvate kinase type ...... tastasizing pancreatic lesions
@nl
prefLabel
TUM2-PK (pyruvate kinase type ...... tastasizing pancreatic lesions
@ast
TUM2-PK (pyruvate kinase type ...... tastasizing pancreatic lesions
@en
TUM2-PK (pyruvate kinase type ...... tastasizing pancreatic lesions
@nl
P2093
P1433
P1476
TUM2-PK (pyruvate kinase type ...... tastasizing pancreatic lesions
@en
P2093
A el-Shabrawi
G Werkgartner
H Cerwenka
H J Mischinger
P304
P407
P577
1999-01-01T00:00:00Z